PATENT CLAIM ANALYSIS

Application Number: 16053540
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["424", "174100"]

Abstract:
The present invention relates to therapeutic combinations and methods for treating cancers using combination therapy.

Claim (Index 4):
The combination of  claim 3 , wherein the PD-1 binding antagonist is an antibody fragment.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 96.0
- Lexical Diversity: 1.0
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15110685', '15793820', '15110690', '15849436', '15849470']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7404819282971228
- 35 USC 102 Novelty (BERT): 0.5424783972309114
- Combined Prediction Score: 0.7206815751905016
- Mean Citation Score: 340.2965880000001
- Max Citation Score: 374.08197
- Similarity Product: 246.1046393194985

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test